Innova Biosciences Introduces Lightning-Link Rapid Bioconjugation Kits
Innova Biosciences, a specialist provider of bioconjugation products and services, has launched new antibody and protein labelling kits within its Lightning-Link Rapid range. These kits enable researchers to label primary antibodies or other proteins in just 20 minutes.
Dyes recently launched within this range include high sensitivity Atto dyes and Cy dyes. Innova has also released a rapid biotin conjugation kit which allows for extremely quick protein biotinylation. Despite the short incubation time, the conjugation reaction is sufficient to achieve conjugates with performance characteristics identical to, or better than, those prepared with laborious multistep conjugation procedures.
Lightning-Link is an innovative technology that enables direct labelling of antibodies, proteins, peptides or other biomolecules for use in R&D applications, drug discovery and the development of diagnostic kits. The procedure is easy to use, involves only 30 seconds of hands-on time, and no spin or separation steps are required. In addition, by circumventing the desalting or dialysis steps that commonly interrupt traditional protein labelling procedures, Lightning-Link Rapid technology can be used to label small quantities of antibody with 100% recovery.
Dr Nick Gee, CEO at Innova, said: "The launch of the Lightning-Link kits completes the development of our Rapid conjugation range, and follows on from the success of the original kits, which had a much longer reaction time. This latest product introduction underlines Lightning-Link as one of the world’s leading bioconjugation technologies, offering easy-to-use labelling that provides excellent results with minimal hands on time and 100% yield.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...